SGT-501 clinical trials

A Study of SGT-501 Gene Therapy in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

This study is testing a new gene therapy called SGT-501 for a heart condition called CPVT. It's the first time this therapy is being used in people, and doctors want to check if it's safe and how much to give. They will watch participants closely for five years.